B. Riley Securities Reiterates Buy on Journey Medical, Raises Price Target to $15

Benzinga Newsdesk www.benzinga.com Positive 80.0%

Neg 0% Neu 0% Pos 80%

B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $12 to $15.